Phosphodiesterase 4D and heart failure: a cautionary tale

Author： Lehnart Stephan E   Marks Andrew R  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.10, Iss.5, 2006-10, pp. : 677-688

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure

By Movsesian M.A.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 5, 2000-05 ,pp. : 963-973

Informa Healthcare

Access to resources Recommend Favorite

The pathophysiology of heart failure: a tale of two old paradigms revisited

By Ashrafian Houman   Williams Lynne   Frenneaux Michael P  

Clinical Medicine, Vol. 8, Iss. 2, 2008-04 ,pp. : 192-197

Royal College Of Physicians

Access to resources Recommend Favorite

3D-QSAR of Novel Phosphodiesterase-4 Inhibitors by Genetic Function Approximation

By  

Medicinal Chemistry, Vol. 7, Iss. 6, 2011-11 ,pp. : 543-552

Bentham Science Publishers

Access to resources Recommend Favorite

Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure

By  

Current Pharmaceutical Design, Vol. 17, Iss. 18, 2011-06 ,pp. : 1794-1807

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 4 inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 4, 1997-04 ,pp. : 385-387

Informa Healthcare

Access to resources Recommend Favorite